Kidney Cancer Canada is once again developing a submission for the pan-Canadian Oncology Drug Review (pCODR). This time the new treatment is pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the first-line treatment of patients with advanced renal cell carcinoma.  We are specifically seeking input from patients with experience with this drug combination (pembrolizumab+axitinib).

If you have used this treatment, your insights and experience will  help inform our submission for the drug combination under review by the pan-Canadian Oncology Drug Review.

This survey will take  approximately 10 minutes to complete. We ask that you complete the survey by August 13. 

If you have any questions about this survey, please write to us at and include Patient and Caregiver Survey in the subject line of the email.

Privacy Policy: All survey data is being collected by Kidney Cancer Canada (KCC), a charitable patient-led support and advocacy group registered with pCODR. To ensure patient privacy and confidentiality, individual responses will not be identifiable. Although selected quotations may be used for the final submission to government agencies, no reference to patient name or any other identifying information will be included.

Thank you for your participation!